PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för LY404039. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

14 hits

Bibliografisk träff 2020-05-13

Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.

Kantrowitz JT, Grinband J, Goff DC, Lahti AC, Marder SR, Kegeles LS, Girgis RR, Sobeih T, Wall MM, Choo TH, Green MF, Yang YS, Lee J, Horga G, Krystal JH, Potter WZ, Javitt DC, Lieberman JA.

Neuropsychopharmacology · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1038/s41386-020-0706-z

Bibliografisk träff 2019-05-01

LY404039 Inhibits Proliferation and Metastasis of Osteosarcoma Cells via PI3K Signaling Pathway.

Wu S, Feng Z, Wei B, Jiang L.

Ann Clin Lab Sci · journal article

Bibliografisk träff 2015-03-09

In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug.

Moulton RD, Ruterbories KJ, Bedwell DW, Mohutsky MA.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.114.062893

Bibliografisk träff 2014-11-07

Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).

Annes WF, Long A, Witcher JW, Ayan-Oshodi MA, Knadler MP, Zhang W, Mitchell MI, Cornelissen K, Hall SD.

J Pharm Sci · clinical trial; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1002/jps.24226

Bibliografisk träff 2014-01-30

mGlu(2) receptor-mediated modulation of conditioned avoidance behavior in rats.

Megens AA, Hendrickx HM, Hens KA, Talloen WJ, Lavreysen H.

Eur J Pharmacol · comparative study; journal article · DOI 10.1016/j.ejphar.2014.01.044

Bibliografisk träff 2013-05-22

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.

Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.

BMC Psychiatry · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1186/1471-244x-13-143

Bibliografisk träff 2012-07-04

An agonist at glutamate and dopamine D2 receptors, LY404039.

Seeman P.

Neuropharmacology · letter · DOI 10.1016/j.neuropharm.2012.07.001

Bibliografisk träff 2011-08-17

Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.

Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K.

Psychopharmacology (Berl) · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s00213-011-2427-9

Bibliografisk träff 2010-07-01

LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.

Mezler M, Geneste H, Gault L, Marek GJ.

Curr Opin Investig Drugs · clinical trial, phase ii; randomized controlled trial; journal article

Bibliografisk träff 2008-04-18

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

Fell MJ, Svensson KA, Johnson BG, Schoepp DD.

J Pharmacol Exp Ther · comparative study; journal article · DOI 10.1124/jpet.108.136861

Bibliografisk träff 2008-01-01

Neither typical nor atypical: LY404039 provides proof of concept that selective targeting of mGluR2/3 receptors is a valid mechanism for obtaining antipsychotic efficacy.

Lebois EP.

Curr Top Med Chem · journal article · DOI 10.2174/156802608786264209

Bibliografisk träff 2007-03-24

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD.

Psychopharmacology (Berl) · journal article · DOI 10.1007/s00213-007-0758-3

Bibliografisk träff 2007-01-04

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther · comparative study; journal article · DOI 10.1124/jpet.106.110809

Bibliografisk träff 2006-05-06

The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats.

Rodd ZA, McKinzie DL, Bell RL, McQueen VK, Murphy JM, Schoepp DD, McBride WJ.

Behav Brain Res · comparative study; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1016/j.bbr.2006.03.032